317 related articles for article (PubMed ID: 31202081)
1. Preclinical therapeutic targets in diffuse midline glioma.
Meel MH; Kaspers GJL; Hulleman E
Drug Resist Updat; 2019 May; 44():15-25. PubMed ID: 31202081
[TBL] [Abstract][Full Text] [Related]
2. Mutations in chromatin machinery and pediatric high-grade glioma.
Lulla RR; Saratsis AM; Hashizume R
Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.
Noon A; Galban S
Neoplasia; 2023 Jun; 40():100899. PubMed ID: 37030112
[TBL] [Abstract][Full Text] [Related]
4. A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.
Jackson ER; Persson ML; Fish CJ; Findlay IJ; Mueller S; Nazarian J; Hulleman E; van der Lugt J; Duchatel RJ; Dun MD
Neuro Oncol; 2024 May; 26(Supplement_2):S136-S154. PubMed ID: 37589388
[TBL] [Abstract][Full Text] [Related]
5. Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.
Lin F; de Gooijer MC; Hanekamp D; Brandsma D; Beijnen JH; van Tellingen O
CNS Oncol; 2013 May; 2(3):271-88. PubMed ID: 25054467
[TBL] [Abstract][Full Text] [Related]
6. [Diffuse midline glioma].
Saito R
No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
[TBL] [Abstract][Full Text] [Related]
7. Histone-Mutant Glioma: Molecular Mechanisms, Preclinical Models, and Implications for Therapy.
Graham MS; Mellinghoff IK
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003625
[TBL] [Abstract][Full Text] [Related]
8. Emerging targeted therapies for glioma.
Miller JJ; Wen PY
Expert Opin Emerg Drugs; 2016 Dec; 21(4):441-452. PubMed ID: 27809598
[TBL] [Abstract][Full Text] [Related]
9. Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma.
Georgescu MM; Islam MZ; Li Y; Circu ML; Traylor J; Notarianni CM; Kline CN; Burns DK
Acta Neuropathol Commun; 2020 Jul; 8(1):111. PubMed ID: 32680567
[TBL] [Abstract][Full Text] [Related]
10. The potential roles of aquaporin 4 in malignant gliomas.
Lan YL; Wang X; Lou JC; Ma XC; Zhang B
Oncotarget; 2017 May; 8(19):32345-32355. PubMed ID: 28423683
[TBL] [Abstract][Full Text] [Related]
11. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
Pachocki CJ; Hol EM
J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
[TBL] [Abstract][Full Text] [Related]
12. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells.
Feng R; Dong L
Int J Clin Exp Pathol; 2015; 8(6):6107-16. PubMed ID: 26261488
[TBL] [Abstract][Full Text] [Related]
14. Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma.
Dahl NA; Danis E; Balakrishnan I; Wang D; Pierce A; Walker FM; Gilani A; Serkova NJ; Madhavan K; Fosmire S; Green AL; Foreman NK; Venkataraman S; Vibhakar R
Cell Rep; 2020 Apr; 31(1):107485. PubMed ID: 32268092
[TBL] [Abstract][Full Text] [Related]
15. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
[TBL] [Abstract][Full Text] [Related]
16. Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.
Rechberger JS; Bouchal SM; Power EA; Nonnenbroich LF; Nesvick CL; Daniels DJ
Expert Opin Ther Targets; 2023; 27(11):1071-1086. PubMed ID: 37897190
[TBL] [Abstract][Full Text] [Related]
17. Histone H3 K27M-mediated regulation of cancer cell stemness and differentiation in diffuse midline glioma.
Sharma M; Barravecchia I; Magnuson B; Ferris SF; Apfelbaum A; Mbah NE; Cruz J; Krishnamoorthy V; Teis R; Kauss M; Koschmann C; Lyssiotis CA; Ljungman M; Galban S
Neoplasia; 2023 Oct; 44():100931. PubMed ID: 37647805
[TBL] [Abstract][Full Text] [Related]
18. Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas.
Kambhampati M; Panditharatna E; Yadavilli S; Saoud K; Lee S; Eze A; Almira-Suarez MI; Hancock L; Bonner ER; Gittens J; Stampar M; Gaonkar K; Resnick AC; Kline C; Ho CY; Waanders AJ; Georgescu MM; Rance NE; Kim Y; Johnson C; Rood BR; Kilburn LB; Hwang EI; Mueller S; Packer RJ; Bornhorst M; Nazarian J
Sci Rep; 2020 Jul; 10(1):10954. PubMed ID: 32616776
[TBL] [Abstract][Full Text] [Related]
19. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]